DXEK has direct effect on corneal hysteresis & biomechanics

Article

Descemetorhexis with endokeratoplasty (DXEK) has a direct effect on corneal hysteresis and the biomechanical properties of the human cornea.

Descemetorhexis with endokeratoplasty (DXEK) has a direct effect on corneal hysteresis and the biomechanical properties of the human cornea, according to Thomas John and colleagues from Loyola University, Chicago, USA.

In this first report on corneal hysteresis and corneal resistance factor following sutureless corneal graft, i.e. DXEK, surgery, 12 eyes of 12 DXEK patients (group1) and 88 eyes of 44 age-matched normal subjects (group 2) were studied. All DXEK subjects were operated on by a single surgeon and the donor corneal disks were surgeon-cut, using the microkeratome and artificial anterior chamber (Moria). None of the eyes had anterior corneal slits to the host-donor interface and all subjects underwent corneal biomechanical evaluation with the Reichert ocular response analyser (ORA).

It was discovered that ORA corneal hysteresis measurements were significantly lower in the DXEK patients (6.94±1.65) than in normal subjects (10.51±1.22). DXEK also had a direct effect on the biomechanical properties of the human cornea, as evidenced by the corneal resistance factor measurements (group1: 8.60±2.10 versus group 2: 9.86±1.23).

The researchers stated that this was the first report of corneal hysteresis and corneal resistance factor following DXEK surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.